Turalio (pexidartinib) is an oral small molecule kinase inhibitor of colony stimulating factor-1 receptor (CSF1R) for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations, and which is not amenable to improvement with surgery.

If you have a Hayes login, click here to view the full report on the Knowledge Center.